Impact of maintenance treatment on male gonadal function in patients treated for localized rhabdomyosarcoma in RMS2005 trial in France

Maintenance treatment with vinorelbine and oral cyclophosphamide (oral‐CPM) improves outcome of nonmetastatic high‐risk (HR) and very‐high risk (VHR) rhabdomyosarcoma (RMS) patients. However, gonadal toxicity of maintenance was not yet investigated.

• Publication year

  2025

• Venue

  Cancer

• Publication date

  2025-05-28

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/cncr.35918PMID 40433871PMCID 12117600
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Impact of maintenance treatment on male gonadal function in patients treated for localized rhabdomyosarcoma in RMS2005 trial in France

  2025cited by this paper
• Frontline and Relapsed Rhabdomyosarcoma (FaR-RMS) Clinical Trial: A Report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG)

  2024cited by this paper
• Maintenance Chemotherapy for Patients with Rhabdomyosarcoma

  2023cited by this paper
• Fertility Preservation and Restoration Options for Pre-Pubertal Male Cancer Patients: Current Approaches

  2022cited by this paper
• Late toxicity comparison of alkylating‐based maintenance regimen with cyclophosphamide (VAC) vs ifosfamide (VAI) in Ewing sarcoma survivors treated in the randomized clinical trial Euro‐EWING99‐R1 in France

  2022cited by this paper
• What should be done in terms of fertility preservation for patients with cancer? The French 2021 guidelines.

  2022cited by this paper
• Fertility preservation for male patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group.

  2021cited by this paper
• Testicular transposition in children before scrotal external radiotherapy

  2020cited by this paper
• Derivation of Anthracycline and Anthraquinone Equivalence Ratios to Doxorubicin for Late-Onset Cardiotoxicity.

  2019cited by this paper
• Defining and listing very rare cancers of paediatric age: consensus of the Joint Action on Rare Cancers in cooperation with the European Cooperative Study Group for Pediatric Rare Tumors.

  2019cited by this paper
• Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial.

  2019cited by this paper
• Testicular transposition in children undergoing brachytherapy for bladder and/or prostate rhabdomyosarcoma.

  2018cited by this paper
• Fusion status in patients with lymph node‐positive (N1) alveolar rhabdomyosarcoma is a powerful predictor of prognosis: Experience of the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG)

  2018cited by this paper
• Follicle Stimulating Hormone is an accurate predictor of azoospermia in childhood cancer survivors

  2017cited by this paper
• Dose–Effect Relationship of Alkylating Agents on Testicular Function in Male Survivors of Childhood Lymphoma

  2015cited by this paper
• Equivalence Ratio for Daunorubicin to Doxorubicin in Relation to Late Heart Failure in Survivors of Childhood Cancer.

  2015cited by this paper
• The cyclophosphamide equivalent dose as an approach for quantifying alkylating agent exposure: A report from the childhood cancer survivor study

  2014cited by this paper
• Testicular function of survivors of childhood cancer: a comparative study between ifosfamide- and cyclophosphamide-based regimens.

  2009cited by this paper
• Effect of childhood cancer treatment on fertility markers in adult male long‐term survivors

  2009cited by this paper
• Does ifosfamide affect gonadal function?

  2008cited by this paper
• Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide.

  2006cited by this paper
• Progress in the development of childhood cancer therapy.

  2006cited by this paper
• Reduced gonadal toxicity after i.v. cyclophosphamide administration in patients with nonmalignant diseases.

  1998cited by this paper

• Building a new arsenal: repurposed drugs and metronomic chemotherapy against medulloblastoma

  2026cites this paper
• Impact of maintenance treatment on male gonadal function in patients treated for localized rhabdomyosarcoma in RMS2005 trial in France

  2025cites this paper
• [A 2025 inventory in oncology news].

  2025cites this paper